J Menopausal Med.  2013 Dec;19(3):123-129. 10.6118/jmm.2013.19.3.123.

Effects of Menopausal Hormone Therapy on Uterine Myoma in Menopausal Women

Affiliations
  • 1Kosin University Graduate School, Busan, Korea.
  • 2Department of Obstetrics and Gynecology, Wonkwang University College of Medicine, Iksan, Korea. hykyale@yahoo.com
  • 3Department of Obstetrics and Gynecology, College of Medicine, Kosin University, Busan, Korea. hykyale@hanmail.net
  • 4Department of Obstetrics and Gynecology, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • 5Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Yangsan, Korea.
  • 6Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul, Korea.

Abstract


OBJECTIVES
The aim of the present study is to evaluate the long term effects of estrogen-progestogen therapy (EPT) on uterine myomas volume in postmenopausal women.
METHODS
We performed a retrospective analysis on postmenopausal women with asymptomatic uterine myoma during the period between April, 2008 and September, 2012. Postmenopause was defined as amenorrhea for longer than a year or serum follicle stimulating hormone levels higher than 40 IU/L. The volume of the myoma was assessed by transvaginal ultrasonography for every 6 months after administration of EPT.
RESULTS
Thirty-eight women were included in the study, with 32 in the EPT group and 6 in the control group. Overall, uterine myoma volume (mean +/- standard deviation, cm3) in the EPT group was 19.5 +/- 24.6 at baseline, and those at 6 and 12 months were 24.7 +/- 35.1 and 28.5 +/- 56.4, respectively. Myoma volume did not change significantly with EPT, and these changes were not significantly different from the control group. Myoma volume changes were not significantly different in the subgroups according to the route of estrogen administrations and the method of progestogen administrations. Clinically significant volume increases during one year of EPT was noted in 28.1% (9/32), however, only one showed transient increases.
CONCLUSION
Our results suggest that treating postmenopausal woman with EPT on a long-term basis does not increase the volume of uterine myomas.

Keyword

Estrogens; Myoma; Postmenopause; Progesterone; Uterus

MeSH Terms

Amenorrhea
Estrogens
Female
Follicle Stimulating Hormone
Humans
Leiomyoma*
Methods
Myoma
Postmenopause
Progesterone
Retrospective Studies
Ultrasonography
Uterus
Estrogens
Follicle Stimulating Hormone
Progesterone

Reference

1. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997; 90:967–973.
2. Schwartz SM. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol. 2001; 44:316–326.
3. Hee LC. Uterine myoma : review of 247 cases. Korean J Obstet Gynecol. 1968; 11:65–73.
4. Sue HS, Nam C, Kim CS, Jang BK, Yang HD, Park SJ. A clinico-statstical study on the myoma of the uterus. Korean J Obstet Gynecol. 1996; 39:1047–1057.
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.
6. Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric. 2001; 4:284–292.
7. Stewart EA. Uterine fibroids. Lancet. 2001; 357:293–298.
8. Colacurci N, De Franciscis P, Cobellis L, Nazzaro G, De Placido G. Effects of hormone replacement therapy on postmenopausal uterine myoma. Maturitas. 2000; 35:167–173.
9. de Aloysio D, Altieri P, Penacchioni P, Salgarello M, Ventura V. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas. 1998; 29:261–264.
10. Fedele L, Bianchi S, Raffaelli R, Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol. 2000; 88:91–94.
11. Palomba S, Sena T, Noia R, Di Carlo C, Zullo F, Mastrantonio P. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol. 2001; 98:1053–1058.
12. Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas. 2000; 37:27–32.
13. Sener AB, Seckin NC, Ozmen S, Gökmen O, Doğu N, Ekici E. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril. 1996; 65:354–357.
14. Simsek T, Karakus C, Trak B. Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. Maturitas. 2002; 42:243–246.
15. Yang CH, Lee JN, Hsu SC, Kuo CH, Tsai EM. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. Maturitas. 2002; 43:35–39.
16. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update. 2004; 10:207–220.
17. Chrapusta S, Sieinski W, Konopka B, Szamborski J, Paszko Z. Estrogen and progestin receptor levels in uterine leiomyomata: relation to the tumour histology and the phase of menstrual cycle. Eur J Gynaecol Oncol. 1990; 11:381–387.
18. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect. 2000; 108:Suppl 5. 791–793.
19. Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand. 1985; 64:307–309.
20. Schwartz SM, Weiss NS, Daling JR, Gammon MD, Liff JM, Watt J, et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer. 1996; 77:717–724.
21. Palomba S, Sena T, Morelli M, Noia R, Zullo F, Mastrantonio P. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2002; 102:199–201.
22. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003; 89:460–469.
23. Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990; 162:968–974. discussion 74-6.
Full Text Links
  • JMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr